

Genetic diversity of chloroquine-resistant *Plasmodium vivax* parasites from the western Brazilian Amazon

Omaira Vera Lizcano^{1/+}, Sarah Stela Resende², Yonne F Chehuan³,
Marcus VG Lacerda³, Cristiana FA Brito², Mariano G Zalis¹

¹Laboratório de Infectologia e Parasitologia Molecular, Serviço de Patologia Clínica, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil ²Laboratório de Malária, Centro de Pesquisa René Rachou-Fiocruz, Belo Horizonte, MG, Brasil ³Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, AM, Brasil

The molecular basis of Plasmodium vivax chloroquine (CQ) resistance is still unknown. Elucidating the molecular background of parasites that are sensitive or resistant to CQ will help to identify and monitor the spread of resistance. By genotyping a panel of molecular markers, we demonstrate a similar genetic variability between in vitro CQ-resistant and sensitive phenotypes of P. vivax parasites. However, our studies identified two loci (MS8 and MSP1-B10) that could be used to discriminate between both CQ-susceptible phenotypes among P. vivax isolates in vitro. These preliminary data suggest that microsatellites may be used to identify and to monitor the spread of P. vivax-resistance around the world.

Key words: *Plasmodium vivax* - chloroquine - resistance

Plasmodium vivax, although less pathogenic than *Plasmodium falciparum*, has a great socioeconomic impact. *P. vivax* has been associated with drug resistance, clinical severity and even fatality (Price et al. 2009). The first cases of *P. vivax* chloroquine resistance (CQ-R) were reported in 1989 in Papua New Guinea (Rieckmann et al. 1989). Since then, reports of CQ-R have been published around the world. Some cases of CQ-R that presented adequate blood CQ levels had been confirmed in Brazil, Ethiopia, Indonesia, Malaysia, Myanmar, Papua New Guinea, Peru, the Solomon Islands and Thailand (WHO 2010). In Brazil, malaria is transmitted along the Amazon Basin. A total of 242,758 cases were reported in 2012, with *P. vivax* accounting for 85% of all cases (WHO 2013). The first reliable case of in vivo CQ-R in Brazil was reported in Manaus, state of Amazonas (AM) (Alecrim et al. 1999). In 2004/2005, 10% of *P. vivax* infections studied in Manaus showed an in vivo CQ-resistant (CQ-Rt) phenotype (Santana Filho et al. 2007). Recently, two studies evaluated *P. vivax* CQ-susceptibility by using short-term in vitro cultures of samples collected in 2004-2008 from AM and confirmed the same prevalence of CQ-R among *P. vivax* parasites (10%) (Chehuan et al. 2013, Pratt-Riccio et al. 2013). In other endemic regions of Brazil, such as in the state of Acre, no CQ-R has been reported (Orjuela-Sánchez et al. 2009) and no studies have been reported so far in other regions of Latin America (Gonçalves et al. 2014).

The genetic mechanism of *P. vivax* CQ-R has yet to be fully elucidated. While CQ-R in *P. falciparum* has been associated with particular point mutations in specific genes, such as *pfprt-o* and *pfmdr-1* (Fidock et al. 2000, Duraisingh & Cowman 2005), this type of association is not very clear in the case of *P. vivax* (Gonçalves et al. 2014). The main difficulty in studying the mechanisms of *P. vivax* CQ-R is the absence of a continuous in vitro culture system, as studies utilising short-term in vitro cultures are useful for investigating drug resistance mechanisms and susceptibility analysis of therapeutic agents for *P. vivax* (Kerlin et al. 2012). Due to the absence of specific molecular markers of resistance, the characterisation of general molecular markers of *P. vivax* will not only help identify CQ-R parasites, but also define the geographical origins and dissemination of resistant isolates (Arnott et al. 2012). The genetic diversity of *P. vivax* has been studied using nearly neutral molecular markers, such as microsatellites (MS) and tandem repeats (TR), as well as with polymorphic antigens, including the PvMSP protein family members (MSP-1 and MSP-3 α) [for a review see de Brito and Ferreira (2011)]. The present study focuses on the genetic diversity of *P. vivax* isolates from the Brazilian Amazon Basin with different CQ-susceptibility phenotypes in short-term in vitro cultures.

Patients with uncomplicated *P. vivax* malaria, as confirmed by a thick blood smear, were randomly selected in the outpatient clinics Dr Heitor Vieira Dourado Tropical Medicine Foundation (Manaus) between December 2007-July 2008. Written informed consent was obtained from all participating patients. The major exclusion criterion was the use of antimalarials within the previous 60 days. Blood was collected at the day of diagnosis and before the start of antimalarial treatment. The patients were treated according to the Brazilian Ministry of Health standards for malaria therapy (Chehuan et al. 2013). Eleven isolates from the Amazon Basin were evaluated: nine from AM, one from the state

doi: 10.1590/0074-0276140241

Financial support: CAPES, FAPEAM, CNPq
CFAB and MVGL receive scholarship from CNPq.
+ Corresponding author: vera.omaira@gmail.com

Received 9 July 2014

Accepted 1 October 2014

TABLE I
Molecular markers characterisation

Marker	First position ^a	Chromosome	Repeating unit	Size fragments
MN21	1567132	8	CCACT	254-290
MN23	1565219	8	CACC	219-302
MS2	782947	3	CA12	290-312
MS5	30333	3	CAT10	173-215
MS6	2835596	14	TGA19	194-298
MS7	152239	2	TAA22	349-388
MS8	1561308	13	TGTA7	284-560
MSP1-B2	1157742	7	Putaporntip	352-460
MSP1-B10			et al. (2002)	226-329

^a: GenBank accession NC_009913.1 (Rezende et al. 2009), chromosome location determined at ncbi.nlm.nih.gov.

of Rondônia (RO) (sample I) and one from the state of Roraima (RR) (sample H). Due to the selective action of CQ on the young trophozoite (ring) stage (Chotivanich et al. 2001), only samples that contained between 50-70% of the total parasite forms at this stage using short-term in vitro culture were evaluated. The CQ-response of the isolates was measured as released plasmodium lactate dehydrogenase using the DELI test and the 50% inhibitory concentration (IC₅₀) values (Chehuan et al. 2013). Samples with IC₅₀ values greater than 100 nM were considered to be CQ-Rt. This study was approved by the Ethical Committee of Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, state of Rio de Janeiro (approval 42746/2012).

Nine neutral markers (Table I), two TRs (MN21 and MN23), five MS (MS2, MS5, MS6, MS7, MS8) and two highly polymorphic blocks of MSP-1 (MSP1-B2 and MSP1-B10) were evaluated by using primers, as described previously (Putaporntip et al. 2002, Feng et al. 2003, Rezende et al. 2009, 2010). These markers have been used previously in studies on the *P. vivax* population structure and diversity in the Brazil endemic area (Rezende et al. 2009, 2010) and in other endemic areas, showing the extent of their polymorphisms (Imwong et al. 2005, Koepfli et al. 2009, 2011).

Plasmodial DNA was extracted from dried blood spots using the QIAamp DNA Micro kit (Qiagen, USA). To increase the quantity of the DNA, parasite DNAs were subjected to whole-genome amplification using a REPLI-g Mini kit (Qiagen) according to the manufacturer's instructions. The markers were amplified using polymerase chain reaction (PCR), according to a previously described methodology (Putaporntip et al. 2002, Feng et al. 2003, Rezende et al. 2009, 2010). The amplified sequences were separated using capillary electrophoresis in an automatic DNA sequencer (MegaBACE, Amersham Biosciences, USA) and the lengths of the products were determined with reference to internal size standards (MegaBACETM ET550-R, Amersham Biosciences) using MegaBACE™

Fragment Profiler v.1.2 software (Amersham Biosciences). The highest peak in the electropherogram was defined as the predominant allele and additional alleles were considered when the corresponding peak heights were at least 1/3 of the height of the predominant allele in the same sample. In all cases, the minimal peak height for an allele to be considered was set to 100 arbitrary fluorescence units. The predominant allele in each *locus* per isolate was used to determine gene diversity using the Arlequin 3.0 software that calculated the expected heterozygosity (H_E), i.e., the probability that a pair of alleles randomly obtained from the population differs from each other.

The six CQ-sensitive (CQ-S) isolates and five CQ-Rt isolates had IC₅₀ medians of 26.35 ng/mL (7.3-66.4) and 152.8 ng/mL (108.8-211.8), respectively. The use of multiple molecular markers showed the usefulness and reproducibility of parasite genotyping, as it could be compared with the population studies performed in Brazil using the same panel of markers (Rezende et al. 2009, 2010, Araujo et al. 2012). The H_E average of CQ-Rt samples ($H_E = 0.528$) and CQ-S samples ($H_E = 0.594$) were comparable because the difference was not statistically significant (Wilcoxon rank sum test, $p = 0.57$). Forty-nine alleles were detected among the samples genotyped using nine *loci*: the more diverse (> 6 alleles) were MSP1-B10, MS7 and MS5, while the more conserved (< 4 alleles) were MS2 and MN23 (Table II). Allelic frequencies ranged from 8.3-80% among the studied samples. For some samples, two alleles were detected at a particular *locus*: CQ-S F (MSP-1 blocks 2 and 10), CQ-S 85 (MS5),

		Molecular markers										
		MN21	MN23	MS2	MS5	MS6	MS7	MS8	M1-B10	M1-B2		
CQ-S	87	290	223		188	203	355	317	267	429		7.3
	F	270	223	298	185	209	364	325	240	429		8.5
	85	290	223		182	203	355	317	267	429		21.6
	C	266	223	302	179	257	361	317	219	415		31.1
	G	290		294	179	209	436	329		417		47.3
	A	258	223	302	182	209	397	317	222	415		66.4
CQ-Rt	J	258	223	298	176	197	355	301	225			108.8
	I	270	223	298	188	209	352	313	258	403		119.0
	E	278	263	298	197	209	355	313	258	403		152.8
	H	258	263	298	191	257	361	313	329	429		178.7
		278	223	298	182	257	442		225			211.8
	B	278	223	298	182	257	442		225			211.8

Genetic variability of chloroquine sensitive (CQ-S) and CQ-resistant (CQ-Rt) *Plasmodium vivax* assessed using tandem repeats (MN21 and MN23), microsatellites (MS2, MS6, MS7 and MS8) and polymorphic antigens, MSP-1 block 2 and 10 (M1-B2 and M1-B10). Predominant alleles (highest peaks on electropherogram) shared by CQ-S and CQ-Rt phenotype are showed in orange, alleles exclusive of CQ-S phenotype in yellow and exclusive of CQ-Rt phenotype in red. Numbers indicate the size of amplified fragment in base pairs. Samples are showed in increasing order of 50% inhibitory concentration (IC₅₀) (right side). Black rectangle highlighted the two markers showing all alleles as phenotype-exclusive. Blank rectangles represent fail in polymerase chain reaction amplification.

TABLE II
Fragment sizes and allele frequency from *Plasmodium vivax* isolates from endemic area de Amazon Basin

Allele number	Tandem repeats Size ^a (%)		Microsatellites Size ^a (%)					Surface antigen Size ^a (%)	
	MN21	MN23	MS2	MS5	MS6	MS7	MS8	MSP1-B2	MSP1-B10
1	258 (27.3)	233 (80)	294 (11)	176 (8.3)	197 (8.3)	352 (8.3)	294 (9.1)	403 (20)	219 (8.3)
2	266 (9)	263 (20)	298 (67)	179 (16.7)	203 (16.7)	355 (33.3)	301 (9.1)	415 (30)	222 (8.3)
3	270 (18.2)	-	302 (22)	182 (25)	209 (41.7)	361 (16.7)	313 (27.3)	417 (10)	225 (16.7)
4	278 (18.2)	-	-	185 (16.7)	240 (8.3)	364 (8.3)	317 (36.4)	429 (40)	240 (8.3)
5	290 (27.3)	-	-	188 (16.7)	257 (25)	397 (8.3)	325 (9.1)	-	243 (8.3)
6	-	-	-	191 (8.3)	-	436 (8.3)	329 (9.1)	-	252 (8.3)
7	-	-	-	197 (8.3)	-	442 (8.3)	-	-	258 (16.7)
8	-	-	-	-	-	445 (8.3)	-	-	267 (16.7)
9	-	-	-	-	-	-	-	-	329 (8.3)
Samples amplified	11	10	9	11	11	11	10	9	10
H _E CQ-S	0.80	0.00	0.63	0.72	0.61	0.77	0.50	0.61	0.71
H _E CQ-Rt	0.67	0.48	0.0	0.80	0.64	0.72	0.37	0.44	0.64

a: fragment size in base pair and its frequency; CQ-Rt: chloroquine resistant; CQ-S: CQ-sensitive; H_E: expected heterozygosity.

CQ-S C (MS7 and MS8), CQ-S A (MS6) and CQ-R H (MSP1-B10) (Table III). Interestingly, despite similar genetic variability between CQ-S and CQ-Rt isolates, multiple alleles per *locus* were identified in four out six CQ-S isolates, whereas this was only found in one CQ-Rt sample, suggesting a higher variability among CQ-S *P. vivax* samples. Of note, the different alleles of MS8 and MSP1-B10 *loci* were not shared by the two phenotypes (Figure). Particularly for the MS8 *locus*, allele 317 was detected in 4/6 (67%) CQ-S phenotype samples and allele 313 in 3/4 (75%) CQ-Rt phenotype samples: all of which were from different states of the Amazon Basin (RO, AM and RR). This *locus* is located on chromosome 13 at 166 bp from the 5' end of a gene encoding a hypothetical conserved protein with phosphatidylinositol phosphate kinase activ-

ity and at 1,942 bp from the 3' end of a gene encoding nuclear transport factor 2 (Rezende et al. 2010). CQ-Rt phenotype exclusive alleles found in this study have also been described in other states of the Amazon Basin, such as Amapá, Pará and Mato Grosso (Rezende et al. 2010), suggesting that the CQ-Rt parasite population could be distributed in other regions of the Amazon Basin.

In conclusion, we found that CQ-S and CQ-Rt *P. vivax* parasites are genetically different. Although the level of genetic diversity was similar in the two phenotypes, both phenotypes could be differentiated by at least two *loci*. Furthermore, these phenotype-specific alleles were identified in different endemic areas of Brazil, suggesting the potential of resistance spreading across the whole Amazon Basin. Further studies should be performed with a larger number of samples to confirm these findings. Whether these *loci* are under linkage disequilibrium and involve their flanking genes to impart resistance warrants further investigation.

TABLE III
Multiple alleles at a particular *locus*

Molecular marker	Samples	Alleles
MS5	CQ-S	85
MS6	A	182/185
MS7	C	209/240
MS8	C	361/445
MSP1-B2	F	249/317
MSP1-B10	F	415/429
MSP1-B10	CQ-Rt	240/243
MSP1-B10	H	252/329

CQ-Rt: chloroquine resistant; CQ-S: CQ-sensitive.

REFERENCES

- Alecrim MG, Alecrim W, Macedo V 1999. *Plasmodium vivax* resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon Region. *Rev Soc Bras Med Trop* 32: 67-68.
- Araujo FC, de Rezende AM, Fontes CJ, Carvalho LH, de Brito CFA 2012. Multiple-clone activation of hypnozoites is the leading cause of relapse in *Plasmodium vivax* infection. *PLoS ONE* 7: e49871.
- Arnott A, Barry AE, Reeder JC 2012. Understanding the population genetics of *Plasmodium vivax* is essential for malaria control and elimination. *Malar J* 11: 14.
- Chehuan YF, Costa MR, Costa JS, Alecrim MG, Nogueira F, Silveira H, Brasil LW, Melo GC, Monteiro WM, Lacerda MV 2013. In vitro chloroquine resistance for *Plasmodium vivax* isolates from the western Brazilian Amazon. *Malar J* 12: 226.

- Chotivanich K, Silamut K, Udomsangpetch R, Stepniewska KA, Pukrittayakamee S, Looareesuwan S, White NJ 2001. Ex-vivo short-term culture and developmental assessment of *Plasmodium vivax*. *Trans R Soc Trop Med Hyg* 95: 677-680.
- de Brito CFA, Ferreira MU 2011. Molecular markers and genetic diversity of *Plasmodium vivax*. *Mem Inst Oswaldo Cruz* 106 (Suppl. 1): 12-26.
- Duraisingh MT, Cowman AF 2005. Contribution of the *pfmdr1* gene to antimalarial drug-resistance. *Acta Trop* 94: 181-190.
- Feng X, Carlton JM, Joy DA, Mu J, Furuya T, Suh BB, Wang Y, Barnwell JW, Su XZ 2003. Single-nucleotide polymorphisms and genome diversity in *Plasmodium vivax*. *Proc Natl Acad Sci USA* 100: 8502-8507.
- Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE 2000. Mutations in the *P. falciparum* digestive vacuole transmembrane protein PFCRT and evidence for their role in chloroquine resistance. *Mol Cell* 6: 861-871.
- Gonçalves LA, Cravo P, Ferreira MU 2014. Emerging *Plasmodium vivax* resistance to chloroquine in South America: an overview. *Mem Inst Oswaldo Cruz* 109: 534-539.
- Imwong M, Pukrittayakamee S, Grüner AC, Rénia L, Letourneur F, Looareesuwan S, White NJ, Snounou G 2005. Practical PCR genotyping protocols for *Plasmodium vivax* using Pvc and Pvm-sp1. *Malar J* 4: 13.
- Kerlin DH, Boyce K, Marfurt J, Simpson JA, Kenangalem E, Cheng Q, Price RN, Gattton ML 2012. An analytical method for assessing stage-specific drug activity in *Plasmodium vivax* malaria: implications for ex vivo drug susceptibility testing. *PLoS Negl Trop Dis* 6: e1772.
- Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, Genton B, Beck HP, Felger I 2009. Evaluation of *Plasmodium vivax* genotyping markers for molecular monitoring in clinical trials. *J Infect Dis* 199: 1074-1080.
- Koepfli C, Ross A, Kiniboro B, Smith TA, Zimmerman PA, Siba P, Mueller I, Felger I 2011. Multiplicity and diversity of *Plasmodium vivax* infections in a highly endemic region in Papua New Guinea. *PLoS Negl Trop Dis* 5: e1424.
- Orjuela-Sánchez P, da Silva NS, da Silva-Nunes M, Ferreira MU 2009. Recurrent parasitemias and population dynamics of *Plasmodium vivax* polymorphisms in rural Amazonia. *Am J Trop Med Hyg* 81: 961-968.
- Pratt-Riccio LR, Chehuan YF, Siqueira MJ, Alecrim MG, Bianco-Júnior C, Druilhe P, Brasseur P, Ferreira-da-Cruz MF, Carvalho LJ, Daniel-Ribeiro CT 2013. Use of a colorimetric (DELD) test for the evaluation of chemoresistance of *Plasmodium falciparum* and *Plasmodium vivax* to commonly used anti-plasmodial drugs in the Brazilian Amazon. *Malar J* 12: 281.
- Price RN, Douglas NM, Anstey NM 2009. New developments in *Plasmodium vivax* malaria: severe disease and the rise of chloroquine resistance. *Curr Opin Infect Dis* 22: 430-435.
- Putaporntip C, Jongwutiwes S, Sakihama N, Ferreira MU, Kho WG, Kaneko A, Kanbara H, Hattori T, Tanabe K 2002. Mosaic organization and heterogeneity in frequency of allelic recombination of the *Plasmodium vivax* merozoite surface protein-1 locus. *Proc Natl Acad Sci USA* 99: 16348-16353.
- Rezende AM, Tarazona-Santos E, Couto AD, Fontes CJ, de Souza JM, Carvalho LH, Brito CF 2009. Analysis of genetic variability of *Plasmodium vivax* isolates from different Brazilian Amazon areas using tandem repeats. *Am J Trop Med Hyg* 80: 729-733.
- Rezende AM, Tarazona-Santos E, Fontes CJ, Souza JM, Couto AD, Carvalho LH, Brito CF 2010. Microsatellite loci: determining the genetic variability of *Plasmodium vivax*. *Trop Med Int Health* 15: 718-726.
- Rieckmann KH, Davis DR, Hutton DC 1989. *Plasmodium vivax* resistance to chloroquine? *Lancet* 2: 1183-1184.
- Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, Vieira JL, Barbosa MD, Alecrim WD, Alecrim MD 2007. Chloroquine resistant *Plasmodium vivax*, Brazilian Amazon. *Emerg Infect Dis* 13: 1125-1126.
- WHO - World Health Organization 2010. Global report on antimalarial efficacy and drug resistance. Available from: who.int/malaria/world_malaria_report_2010/worldmalariareport2010.pdf.
- WHO - World Health Organization 2013. World Malaria Report 2013. Available from: who.int/malaria/publications/world_malaria_report_2013/en/.